Drug interaction between methamphetamine and antihistamines: behavioral changes and tissue concentrations of methamphetamine in rats.

Methamphetamine is a psychomotor stimulant, whereas first generation antihistamines cause sedation. Several studies have demonstrated that first generation antihistamines potentiate methamphetamine-induced psychomotor activation and two possible mechanisms have been postulated. One is blockage of the central histaminergic neuron system and the other is inhibition of dopamine reuptake. However, the exact mechanism is still controversial. In this study, we examined in behavioral tests the effects of selected antihistamines on methamphetamine-induced psychomotor activation in rats, and measured plasma and brain tissue concentrations of methamphetamine. We found that some antihistamines significantly potentiate methamphetamine-induced psychomotor activation in rats and that plasma and brain tissue concentrations of methamphetamine in rats treated with methamphetamine in combination with D-chlorpheniramine were markedly higher than those in rats treated with methamphetamine alone. These results suggest that the potentiating effects of antihistamines are due to not only central effects but also the alteration of the pharmacokinetics of methamphetamine.

[1]  S. Masuda,et al.  Distinct Characteristics of Organic Cation Transporters, OCT1 and OCT2, in the Basolateral Membrane of Renal Tubules , 2001, Pharmaceutical Research.

[2]  T. Hasegawa,et al.  Increased plasma concentration and brain penetration of methamphetamine in behaviorally sensitized rats. , 2003, European journal of pharmacology.

[3]  T. Watanabe,et al.  Effects of histamine agents on methamphetamine-induced stereotyped behavior and behavioral sensitization in rats , 1997, Psychopharmacology.

[4]  K. Yanai,et al.  Methamphetamine and Brain Histamine: A Study Using Histamine‐Related Gene Knockout Mice , 2004, Annals of the New York Academy of Sciences.

[5]  M. Itoh,et al.  Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography , 1995, British journal of pharmacology.

[6]  H. Ohtsu,et al.  Increased methamphetamine‐induced locomotor activity and behavioral sensitization in histamine‐deficient mice , 2002, Journal of neurochemistry.

[7]  J. Tanaka,et al.  Distribution of the histaminergic neuron system in the central nervous system of rats; a fluorescent immunohistochemical analysis with histidine decar☐ylase as a marker , 1984, Brain Research.

[8]  J. Huston,et al.  The tuberomammillary nucleus projections in the control of learning, memory and reinforcement processes: evidence for an inhibitory role , 1997, Behavioural Brain Research.

[9]  M. Nomoto,et al.  Phenytoin potentiates methamphetamine-induced behavior in mice , 1984, Pharmacology Biochemistry and Behavior.

[10]  Rivière Gj,et al.  SPONTANEOUS LOCOMOTOR ACTIVITY AND PHARMACOKINETICS OF INTRAVENOUS METHAMPHETAMINE AND ITS METABOLITE AMPHETAMINE IN THE RAT , 1999 .

[11]  M. Hiratsuka,et al.  Brain and heart specific alteration of methamphetamine (MAP) distribution in MAP-sensitized rat. , 2003, Biological and Pharmaceutical Bulletin.

[12]  H. Hoffman,et al.  Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input. , 1980, Psychological review.

[13]  A. Sharma,et al.  Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view. , 2003, Current drug metabolism.

[14]  R. Oishi,et al.  In vivo effects of some histamine H1-receptor antagonists on monoamine metabolism in the mouse brain , 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.

[15]  B. Costall,et al.  The relationship between the inhibition of dopamine uptake and the enhancement of amphetamine stereotypy. , 1971, Life sciences. Pt. 1: Physiology and pharmacology.

[16]  R. Blakely,et al.  Pharmacological profile of neuroleptics at human monoamine transporters. , 1999, European journal of pharmacology.

[17]  B. Drolet,et al.  In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[18]  T. Edeki,et al.  Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes , 2002, European Journal of Clinical Pharmacology.

[19]  H. Haas,et al.  The role of histamine and the tuberomamillary nucleus in the nervous system , 2003, Nature Reviews Neuroscience.

[20]  M. Nishibori,et al.  Neuronal histamine inhibits methamphetamine-induced locomotor hyperactivity in mice , 1984, Neuroscience Letters.

[21]  R. Oishi,et al.  Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain , 1994, Naunyn-Schmiedeberg's Archives of Pharmacology.

[22]  R. Blakely,et al.  Pharmacological profile of antidepressants and related compounds at human monoamine transporters. , 1997, European journal of pharmacology.

[23]  P. Panula,et al.  Histamine-containing neurons in the rat hypothalamus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Haas,et al.  The physiology of brain histamine , 2001, Progress in Neurobiology.

[25]  J. Balsara,et al.  Effect of drugs influencing central serotonergic mechanisms on methamphetamine-induced stereotyped behavior in the rat , 1979, Psychopharmacology.

[26]  L. Iversen,et al.  REGIONAL STUDIES OF CATECHOLAMINES IN THE RAT BRAIN‐I , 1966, Journal of neurochemistry.

[27]  T. Watanabe,et al.  Studies on functional roles of the histaminergic neuron system by using pharmacological agents, knockout mice and positron emission tomography. , 2001, The Tohoku journal of experimental medicine.

[28]  G. Tucker,et al.  Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[29]  B. Katzung.  Basic and Clinical Pharmacology , 1982 .